CAMR was successful in that the one time a generic company tried to use the mechanism, it worked in less than 70 days. We have not had failures. We have not had a number of generic companies try to use the program and not be able to use it.
I can't determine when the generics will choose to use it or not to use it. Is it a question that there's not a need for it? Is it a question that there's a safety valve that exists to meet needs where they aren't being met through other programs internationally? I can't answer for their choices for not using it, but when used, it worked.